Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.3.1.900
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Consolidated Statements Of Operations    
Revenues, net $ 924,732 $ 1,170,922
Operating expenses:    
Cost of implants and other costs 151,970 220,959
Selling, general and administrative 2,125,882 $ 3,867,047
Termination of licensing agreement 3,639,694
Depreciation and amortization 125,070 $ 135,491
Total operating expenses 6,042,616 4,223,497
Net loss from operations (5,117,884) $ (3,052,575)
Other income (expenses):    
Net gain on settlement agreement 731,973
Interest expense, net (377,087) $ (352,799)
Gain on change in fair value of derivative liability 97,008 277,594
Total other income (expenses) 451,894 (75,205)
Loss before income taxes $ (4,665,990) $ (3,127,780)
Income taxes
Net loss $ (4,665,990) $ (3,127,780)
Net loss per common share, basic and diluted $ (0.03) $ (0.02)
Weighted average number of common shares outstanding, basic and diluted 155,487,569 138,876,761